News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
834,533 Results
Type
Article (85785)
Company Profile (649)
Press Release (748099)
Section
Business (232105)
Career Advice (4121)
Deals (39690)
Drug Delivery (124)
Drug Development (90699)
Employer Resources (195)
FDA (17951)
Job Trends (17295)
News (395295)
Policy (39616)
Tag
Academia (2977)
Alliances (56581)
Alzheimer's disease (1403)
Antibody-drug conjugate (ADC) (112)
Approvals (17933)
Artificial intelligence (183)
Bankruptcy (399)
Best Places to Work (12511)
Biotechnology (447)
Breast cancer (190)
Cancer (1565)
Career advice (3523)
CAR-T (130)
Cell therapy (376)
Clinical research (72192)
Collaboration (633)
Compensation (315)
COVID-19 (2812)
C-suite (150)
Data (1418)
Diabetes (153)
Diagnostics (6706)
Earnings (94559)
Employer resources (166)
Events (127339)
Executive appointments (493)
FDA (18677)
Funding (541)
Gene therapy (262)
GLP-1 (689)
Government (5051)
Healthcare (20717)
Infectious disease (2903)
Inflammatory bowel disease (134)
Interviews (810)
IPO (17708)
Job creations (5182)
Job search strategy (2859)
Layoffs (510)
Legal (10043)
Lung cancer (235)
Manufacturing (226)
Medical device (14298)
Medtech (14303)
Mergers & acquisitions (22197)
Metabolic disorders (494)
Neuroscience (1791)
NextGen: Class of 2025 (7661)
Non-profit (5053)
Northern California (1863)
Obesity (273)
Opinion (259)
Patents (148)
People (64525)
Pharmaceutical (131)
Phase I (22297)
Phase II (31392)
Phase III (23589)
Pipeline (644)
Postmarket research (3541)
Preclinical (10003)
Radiopharmaceuticals (250)
Rare diseases (310)
Real estate (7375)
Regulatory (26149)
Research institute (2640)
Resumes & cover letters (649)
Southern California (1613)
Startups (4277)
United States (16679)
Vaccines (669)
Weight loss (205)
Date
Today (9)
Last 7 days (515)
Last 30 days (2120)
Last 365 days (32529)
2025 (3800)
2024 (34411)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1262)
Arizona (231)
Asia (49568)
Australia (8750)
California (4312)
Canada (1399)
China (377)
Colorado (144)
Connecticut (186)
Europe (113415)
Florida (544)
Georgia (118)
Illinois (405)
Indiana (237)
Maryland (736)
Massachusetts (3428)
Michigan (171)
Minnesota (289)
New Jersey (1214)
New York (1211)
North Carolina (901)
Northern California (1863)
Ohio (145)
Pennsylvania (939)
South America (1646)
Southern California (1613)
Texas (592)
Washington State (449)
834,533 Results for "belite bio llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Belite Bio Announces Registered Direct Offering of $15 Million
February 5, 2025
·
3 min read
Policy
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Belite Bio, Inc announces that its lead pipeline, Tinlarebant, has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan for the treatment of STGD1.
June 12, 2024
·
5 min read
Biotech Beach
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced the presentation at Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) being held May 5 – 9, 2024, in Seattle, WA.
May 1, 2024
·
5 min read
Business
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
Belite Bio, Inc announced its financial results for the first quarter ended March 31, 2024 and provided a general business update.
May 13, 2024
·
10 min read
Biotech Beach
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
Belite Bio, Inc. today announced that the executive management team will participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024.
May 14, 2024
·
1 min read
Biotech Beach
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
Belite Bio, Inc. (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced additional findings from the 24-month Phase 2 study of Tinlarebant in adolescent Stargardt disease (STGD1) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
May 6, 2024
·
8 min read
Press Releases
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 12, 2024
·
10 min read
Biotech Beach
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
Belite Bio, Inc. today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024.
March 4, 2024
·
1 min read
Press Releases
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
November 4, 2024
·
3 min read
Business
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
Belite Bio, Inc today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024.
May 8, 2024
·
1 min read
1 of 83,454
Next
